Apr 11, 2019
NLRP3 EARLY AND OFTEN
NLRP3 early and often
Inflammasome inhibitors could offer a step change for a slew of inflammatory diseases and pharma is taking notice. Two acquisitions in six months show the first inflammasome target — NLRP3 — is gaining momentum, but the question is how fast drug developers can discern the best set of indications from the sea of possibilities.